NOW APPROVED

ESKATA single use applicator pen

ESKATA™ is now approved for the treatment of raised seborrheic keratoses.

Register for Updates

Register here if you are interested in receiving more information about ESKATA or being contacted by an Aclaris sales representative.

*Required Field

I am interested in*:

Please confirm

By checking this box, I consent that the information I am providing may be used by Aclaris Therapeutics, Inc., its affiliates or vendors to keep me informed about products, patient support services, special offers, or other opportunities that may be of interest to me via mail and email. These materials may contain information that market or advertise Aclaris Therapeutics, Inc. products, goods, or services.

I may opt out at any time by clicking the unsubscribe link within any email I receive, or by sending a letter with my request to Aclaris Therapeutics, Inc., 640 Lee Road, Suite 200, Wayne, PA 19087. By providing my information to Aclaris Therapeutics, Inc. I certify I am at least eighteen (18) years of age and agree to the terms above.

Please fill out all required fields

Register now

Availability

  • AVAILABILITY

    ESKATA will be available to healthcare providers in the spring of 2018.

  • ORDERING

    Pre-ordering will be available 2 weeks prior to product availability. To sign up to pre-order, register here.

ESKATA packaging

Application

Watch the ESKATA Application video

About Aclaris

Aclaris logo

Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunodermatology. The company is focused on market segments with no FDA-approved medications or where treatment gaps exist.

FAQ

DOWNLOAD PRESCRIBING INFORMATION

IMPORTANT SAFETY INFORMATION

Indications and Usage

ESKATA (hydrogen peroxide) topical solution, 40% (w/w) is indicated for the treatment of seborrheic keratoses that are raised.

IMPORTANT SAFETY INFORMATION

ESKATA is to be administered by a healthcare provider. For topical use only. Not for ophthalmic use. Not for open or infected seborrheic keratoses.

CONTRAINDICATIONS

None.

WARNINGS AND PRECAUTIONS

Do not apply to the eyes or mucous membranes. Avoid treating seborrheic keratoses within the orbital rim. Direct contact with the eye can cause corneal injury (erosion, ulceration, perforation, and scarring), chemical conjunctivitis, eyelid edema, severe eye pain or permanent eye injury, including blindness. If accidental exposure occurs, flush with water for 15 to 30 minutes, initiate monitoring and further evaluation as appropriate.

Skin reactions occurred in the treatment area after application of ESKATA. Severe local skin reactions included erosion, ulceration, vesiculation and scarring. Do not retreat until the skin has recovered from any reaction caused by the previous treatment.

MOST COMMON ADVERSE REACTIONS

The most common adverse reactions include erythema (99%), stinging (97%), edema (91%), scaling (90%), crusting (81%), and pruritus (58%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see accompanying full Prescribing Information for ESKATA (hydrogen peroxide) topical solution, 40% (w/w).